The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice.

A publication (2017-09-26 | journal article) of the University of Göttingen

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​The BET/BRD inhibitor JQ1 improves brain plasticity in WT and APP mice.​
Benito, E.; Ramachandran, B.; Schroeder, H.; Schmidt, G.; Urbanke, H.; Burkhardt, S. & Capece, V. et al.​ (2017) 
Translational psychiatry7(9) pp. e1239​-e1239​.​

Documents & Media

tp2017202.pdf1.38 MBAdobe PDF

License

Published Version

Attribution 4.0 CC BY 4.0

Details

Authors
Benito, E.
Ramachandran, B.
Schroeder, H.
Schmidt, G.
Urbanke, H.
Burkhardt, S.
Capece, V.
Dean, C.
Fischer, A. 
Abstract
Histone acetylation is essential for memory formation and its deregulation contributes to the pathogenesis of Alzheimer's disease. Thus, targeting histone acetylation is discussed as a novel approach to treat dementia. The histone acetylation landscape is shaped by chromatin writer and eraser proteins, while readers link chromatin state to cellular function. Chromatin readers emerged novel drug targets in cancer research but little is known about the manipulation of readers in the adult brain. Here we tested the effect of JQ1-a small-molecule inhibitor of the chromatin readers BRD2, BRD3, BRD4 and BRDT-on brain function and show that JQ1 is able to enhance cognitive performance and long-term potentiation in wild-type animals and in a mouse model for Alzheimer's disease. Systemic administration of JQ1 elicited a hippocampal gene expression program that is associated with ion channel activity, transcription and DNA repair. Our findings suggest that JQ1 could be used as a therapy against dementia and should be further tested in the context of learning and memory.
Issue Date
26-September-2017
Journal
Translational psychiatry 
Project
info:eu-repo/grantAgreement/EC/H2020/648898/EU//DEPICODE
ISSN
2158-3188
Language
English

Reference

Citations


Social Media